Effect of Fully Blocking Type 1 Angiotensin Receptor on Target Organ Damage of Postmenopausal Hypertensive Women

Effect of Fully Blocking Type 1 Angiotensin Receptor on Blood Pressure, Cardiac Structure, Cardiac Function and Cognitive Function in Postmenopausal Hypertensive Women

Status

UNKNOWN

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03432468

Enrollment

102

Registered

2018-02-14

Start date

2018-04-01

Completion date

2019-08-01

Last updated

2018-03-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertension

Keywords

Hypertension, Left Ventricular Hypertrophy, Women

Brief summary

This study compared the improvements of blood pressure levels, left ventricular hypertrophy, left ventricular diastolic function, vascular function and cognitive function between postmenopausal hypertensive women and age-matched hypertensive male patients through the evaluation of the effects of fully blocked AT1 receptor by valsartan. Additionally, the differences of the above indexes between the patients who were fully blocked AT1 receptor by valsartan and the patients who were treated with a single dose of valsartan treatment were assessed, so as to provide theory basis for clinical treatment of postmenopausal hypertensive women.

Interventions

DRUGValsartan 1

the high dose of valsartan

DRUGValsartan 80 mg

a single dose of valsartan

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

40 Years to 65 Years

Healthy volunteers

Inclusion criteria

* Clinical diagnosis of hypertension * Women are all postmenopausal * Must provide written informed consent

Exclusion criteria

* Secondary hypertension * Coronary disease * Heart failure * Arterial fibrillation * Previous myocardial infarction * Previous stroke * Malignant disease * Kidney failure * Liver failure * Neoplastic disease * Severe neurological diseases * Severe metabolic or organic decompensation * Refuse to sign the informed consent form

Design outcomes

Primary

Measure	Time frame	Description
Relative indexes of myocardial remodeling	Change from Baseline left ventricular mass index at 6 months.	Cardiac structure (left ventricular mass index in grams for square meter) measurement.
Ambulatory blood pressure monitoring	Change from Baseline ABPM at 6 months.	Non-invasive ambulatory blood pressure monitoring (ABPM) was performed for every enrolled patient with an ABPM equipment.
Sexual hormones	Baseline sexual hormones.	Blood samples used to analyze the levels of sexual hormones were collected between morning 8:00 and 9:00 after an overnight fast. The sexual hormones which include prolactin (PRL) and progesterone (P) units on nanogram per millilitre, luteinizing hormone (LH) and follicle-stimulating hormone (FSH) units on millionInternationalUnits per millilitre, testosterone (T) in nanogram per deciliter, estradiol (E2) in picogram per millilitre.

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026